Trials Sponsors Conditions Drugs Pricing

Conditions

CoQ10 Blood Levels

Outcome Measures

Primary Outcomes (1)

Net incremental area under the curve (niAUC) for plasma CoQ10
Difference between conditions in the niAUC for plasma CoQ10 from 0 to 24 h where t = 0 is the time of study product ingestion
7 to 14 days between conditions

Secondary Outcomes (5)

Incremental area under the curve (iAUC) for plasma CoQ10
7 to 14 days between conditions
Total area under the curve (AUC) for plasma CoQ10
7 to 14 days between conditions
Unadjusted maximum concentration (Cmax) for plasma CoQ10
7 to 14 days between conditions
Baseline-adjusted maximum concentration (Cmax) for plasma CoQ10
7 to 14 days between conditions
Time to maximum concentration (Tmax) for plasma CoQ10
7 to 14 days between conditions

Study Arms (2)

Experimental - high absorption CoQ10 product

EXPERIMENTAL

100 mg CoQ10 product designed for high absorption (administered as two 50 mg capsules)

Dietary Supplement: high absorption CoQ10 product

Active Comparator - standard CoQ10 product

ACTIVE COMPARATOR

100 mg standard CoQ10 product (administered as two 50 mg capsules)

Dietary Supplement: standard CoQ10 product

Interventions

high absorption CoQ10 productDietary supplement

100 mg CoQ10 product designed for high absorption (administered as two 50 mg capsules)

Experimental - high absorption CoQ10 product

standard CoQ10 productDietary supplement

100 mg standard CoQ10 product (administered as two 50 mg capsules)

Active Comparator - standard CoQ10 product

Eligibility Criteria

Age21 Years - 65 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Male or female, between 21 and 65 y of age.
Individual has a BMI of 18.5 to 34.9 kg/m2.

Sponsors & Collaborators

Midwest Center for Metabolic and Cardiovascular Research
Otherlead
Pharmavite LLC
Industrycollaborator

Study Sites (1)

Biofortis Clinical Research

Addison, Illinois, 60101, United States

Enrollment

24 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: OTHER
Intervention Model: CROSSOVER
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 7, 2026

First Posted

April 15, 2026

Study Start

May 18, 2026

Actual (reported)

You may not qualify if:

Individual has any gastrointestinal condition that could potentially interfere with absorption of the study product (e.g., inflammatory bowel syndrome, celiac disease, history of gastric bypass surgery).
Individual has a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, or stroke), pulmonary, renal, hepatic, or biliary disorders.
Individual has had any major trauma or surgical event within 12 weeks prior to screening/baseline (visit 1).
Individual has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
Individual has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg) at screening/baseline (visit 1).
Individual has a laboratory test result of clinical significance at screening/baseline (visit 1) based on the judgment of the Principal Investigator or qualified designee.
Individual has signs or symptoms of an active infection of clinical significance (e.g., urinary tract or respiratory) within five days prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have been resolved for at least five days and, if antibiotics were prescribed, antibiotic therapy has been completed at least 7 days prior to the test visit.
Individual has unstable use (defined as initiation or change in dose, agent, or regimen) of statin therapy within 3 months of visit 1.
Individual uses medications or dietary supplements known to interfere with CoQ10 metabolism within 14 days prior to screening/baseline (visit 1) and throughout the study period, including, but not limited to, lipid-lowering (stable dose of statin therapy is allowed), anti-hypertensive, hypoglycemic, anti-coagulant, and psychotherapeutic therapies. For all other medications, individual must be on a stable dose for at least 3 months prior to visit 1.
Use of any prescription medication with known effects on appetite or weight (e.g., oral steroids, weight loss medications, etc.) within 3 months of visit 1. A stable dose of selective serotonin reuptake inhibitors ≥3 months is allowed.
Individual has lost ≥4.5 kg (10 lbs.) in the previous 3 months.
Use of tobacco/nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 6 months of visit 1. Occasional use (defined as less than once per week) within 6 months of visit 1 is allowed but requires that the participant refrain for 24 hours prior to and during test visits.
Individual follows a restricted diet (e.g., vegetarian, vegan, Atkins, etc.).
Individual is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
Individual has a known allergy or sensitivity to any ingredients in the study products or standardized meals/snacks.
+3 more criteria

Assessing Two Coenzyme Q10 Products in Men and Women

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (2)

Experimental - high absorption CoQ10 product

Active Comparator - standard CoQ10 product

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (2)

Experimental - high absorption CoQ10 product

Active Comparator - standard CoQ10 product

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations